LABELS · ea835cc4-6151-4b2e-ad69-3b2c6d32b078

Boncresa

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-12-22
Captured: 2026-09-09T23:38:02.384588+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Boncresa in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Boncresa in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. (5.1) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. (5.1) Prior to initiating Boncresa in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Boncresa in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. (2.2) , (5.1)

Indications and usage: exact source text

1 INDICATIONS AND USAGE Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Boncresa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Boncresa is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Boncresa is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Boncresa is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Boncresa is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

Full extracted label fields

application numbers

BLA761456

boxed warning exact

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE Patients with advanced chronic kidney disease (eGFR <30 mL/min/1.73 m 2 ), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported [see Warnings and Precautions (5.1) ] . The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients [see Warnings and Precautions (5.1) ] . Prior to initiating Boncresa in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Boncresa in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE See full prescribing information for complete boxed warning. Patients with advanced chronic kidney disease are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. (5.1) The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia. (5.1) Prior to initiating Boncresa in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Boncresa in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD. (2.2) , (5.1)

brand names

Boncresa

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=29140df2-24a3-4a6f-a8e3-065521448d61

generic names

DENOSUMAB-MOBZ

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

indications and usage exact

1 INDICATIONS AND USAGE Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Boncresa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Boncresa is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Boncresa is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Boncresa is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Boncresa is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Amneal Pharmaceuticals LLC

matched search terms

cancer

package ndcs

70121-2702-1

product ndcs

70121-2702

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

2729312
2729319

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00700.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

BLA761456

brand names

Boncresa

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 366
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 0

current approval status

not_reconciled

duplicate text group

dup-43a8a57b021ad2d4baa3

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-296161ff6c28906bda94

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 166
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1)
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 445
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Boncresa is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 0

current approval status

not_reconciled

duplicate text group

dup-a5064639f4a5467f7e70

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-696338fdd2bf2c304d20

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 245
end exclusive: true
exact text: to increase bone mass in men with osteoporosis at high risk for fracture (1.2)
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 167

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 3 · unclassified context

application numbers

BLA761456

brand names

Boncresa

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 533
end exclusive: true
exact text: and (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receivin
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 46

current approval status

not_reconciled

duplicate text group

dup-cf095007efe58762f365

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-24f71a2692f1391214da

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 333
end exclusive: true
exact text: of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3)
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 246

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 667
end exclusive: true
exact text: at high risk for fracture (1.1) to increase bone mass in men with osteoporosis at high risk for fracture (1.2) of glucocorticoid-induced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk fo
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 134

current approval status

not_reconciled

duplicate text group

dup-969c6b4df7956ddc08c1

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-7268fd44f38b620f7091

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 467
end exclusive: true
exact text: to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4)
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 334

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 5 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

inherited_predicate_from_same_label_section_requires_review
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 795
end exclusive: true
exact text: ced osteoporosis in men and women at high risk for fracture (1.3) to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Boncresa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 268

current approval status

not_reconciled

duplicate text group

dup-22823d73b4f532f05281

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-769067c557b0cb1483e2

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 77
end exclusive: true
exact text: is a RANK ligand (RANKL) inhibitor indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 33

qualifier mentions

context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5)
kind
stage_or_setting
polarity
not_inferred
span
end
578
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start
535

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 595
end exclusive: true
exact text: to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5)
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 468

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 6 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1159
end exclusive: true
exact text: ng androgen deprivation therapy for nonmetastatic prostate cancer (1.4) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (1.5) 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Boncresa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men wi
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 396

current approval status

not_reconciled

duplicate text group

dup-1b8a9b322b8409a41755

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-70695e907f6dc09f9de6

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 699
end exclusive: true
exact text: is indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 687

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 959
end exclusive: true
exact text: 1.1 Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture Boncresa is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 596

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · unclassified context

application numbers

BLA761456

brand names

Boncresa

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1313
end exclusive: true
exact text: at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Boncresa is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of oste
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 760

current approval status

not_reconciled

duplicate text group

dup-70d024c6a289e04373ca

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-53944a9cb1a67288cc49

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1113
end exclusive: true
exact text: In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] .
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 960

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1689
end exclusive: true
exact text: rant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures [see Clinical Studies (14.1) ] . 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Boncresa is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Boncresa is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 914

current approval status

not_reconciled

duplicate text group

dup-0f4d0410f2a86fb7e5f3

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-7df0e35c5d7b750b4c57

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 1196
end exclusive: true
exact text: is indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1184

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1489
end exclusive: true
exact text: 1.2 Treatment to Increase Bone Mass in Men with Osteoporosis Boncresa is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] .
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1114

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 9 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2057
end exclusive: true
exact text: ed as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.2) ] . 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Boncresa is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1290

current approval status

not_reconciled

duplicate text group

dup-be96ebeab8f9b70538b6

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-b275dbe9bab7b691db53

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 1564
end exclusive: true
exact text: is indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1552

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 1857
end exclusive: true
exact text: 1.3 Treatment of Glucocorticoid-Induced Osteoporosis Boncresa is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1490

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 10 · risk or warning

application numbers

BLA761456

brand names

Boncresa

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 2284
end exclusive: true
exact text: cture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Boncresa is indicated as a treatment to increase bone mass in men at high risk for fracture receiving andr
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1658

current approval status

not_reconciled

duplicate text group

dup-ebd70c3ee93854631df8

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-2f958e17fb624338d013

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2084
end exclusive: true
exact text: High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] .
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1858

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2549
end exclusive: true
exact text: fined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy [see Clinical Studies (14.3) ] . 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Boncresa is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for B
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 1885

current approval status

not_reconciled

duplicate text group

dup-19e14c2bcc9ac01a821c

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-fb945619c7e84e72994e

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 2199
end exclusive: true
exact text: is indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2187

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2349
end exclusive: true
exact text: 1.4 Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Boncresa is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2085

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Passage 12 · unclassified context

application numbers

BLA761456

brand names

Boncresa

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2660
end exclusive: true
exact text: Therapy for Prostate Cancer Boncresa is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Boncresa is indicated as a treatment to increase bone mass in women at high risk for fracture rece
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2150

current approval status

not_reconciled

duplicate text group

dup-0e50680a914b8d66c5c7

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-2513f1d474e2b8c3e6b4

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2460
end exclusive: true
exact text: In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] .
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2350

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

BLA761456

brand names

Boncresa

classification reasons

explicit_positive_indication_predicate
supportive_or_complication_use_words

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2753
end exclusive: true
exact text: fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures [see Clinical Studies (14.4) ] . 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Boncresa is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2261

current approval status

not_reconciled

duplicate text group

dup-f06662bc56b2f5c05a1a

extraction review status

automated_candidate_pending_source_review

generic names

DENOSUMAB-MOBZ

ind-span-207a61bb426ff467710c

label id

ea835cc4-6151-4b2e-ad69-3b2c6d32b078

positive predicate support span

end: 2583
end exclusive: true
exact text: is indicated
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2571

qualifier mentions

context exact
1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Boncresa is indicated as a treatment to increase
kind
stage_or_setting
polarity
not_inferred
span
end
2550
end exclusive
true
exact text
Adjuvant Aromatase Inhibitor Therapy for Br
label id
ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start
2507
context exact
ease bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
kind
stage_or_setting
polarity
not_inferred
span
end
2709
end exclusive
true
exact text
adjuvant aromatase inhibitor therapy for br
label id
ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start
2666

regulatory links

schema version

0.1.0

source batch sha256

24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08

source defined aliases

source span

end: 2753
end exclusive: true
exact text: 1.5 Treatment of Bone Loss in Women Receiving Adjuvant Aromatase Inhibitor Therapy for Breast Cancer Boncresa is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer [see Clinical Studies (14.5) ] .
label id: ea835cc4-6151-4b2e-ad69-3b2c6d32b078
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7dd0142ebec5cc04ac4e69ec674c50ec1dccddfb6e6f2f9428aebb9d31722773
start: 2461

source url

https://api.fda.gov/drug/label.json?search=id%3A%22ea835cc4-6151-4b2e-ad69-3b2c6d32b078%22

spl effective date

2025-12-22

spl set id

29140df2-24a3-4a6f-a8e3-065521448d61

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

supportive_care_candidate

Preserved source evidence · Not medical advice